Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer-Reference-Cited by-同舟云学术

Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer

Published:1995-01 Issue:5 Volume:31 Page:686-690
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Crippa F.,Bolis G.,Seregni E.,Gavoni N.,Scarfone G.,Ferraris C.,Buraggi G.L.,Bombardieri E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Randomized trial comparing two combination chemotherapy regimes (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma;Neijt;Lancet,1984

2. A randomized trial comparing cisplatinum plus cyclophosphamide versus cisplatinum, doxorubicin and cyclophosphamide in advanced ovarian cancer;Conte;J Clin Oncol,1987

3. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

4. Long-term survival after chemotherapy for advanced epithelial ovarian cancer;Wharton;Am J Obst Gynecol,1984

5. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy;Howell;J Clin Oncol,1987

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical application of radioiodinated antibodies: where are we?;Clinical and Translational Imaging;2022-01-11

2. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors;Nucleic Acid Therapeutics;2021-02-01

3. Exploiting the folate receptor α in oncology;Nature Reviews Clinical Oncology;2020-03-09

4. Therapeutic targets and new directions for antibodies developed for ovarian cancer;mAbs;2016-08-05

5. Targeting folate receptor alpha for cancer treatment;Oncotarget;2016-05-27